FDA clears Bayer’s Gadavist as first contrast agent for card...

Bayer may merge animal health unit with Elanco; report

Bayer/J&J eye new paediatric use for anticoagulant Xarelto

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagul

Bayer begins phase 3 trial testing aflibercept in infant bli...

Bayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants.

Bayer's regorafenib kicks off brain cancer platform trial

Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.

Japan approves Roche's tumour agnostic cancer drug Rozlytrek

Japan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib).